Patents cover coformulations with SGLT2 inhibitors, incretin combinations, and thyroid receptor agonist pairings [25, 26], reflecting the clinical reality that many patients will benefit from multi-mechanism approaches
Semaglutide has been approved by the FDA and many other countries regulatory bodies for both of its two main usesmanagement of type 2 diabetes and chronic weight management in adults with obesity or those who are overweight with at least one weight-related condition, such as hypertension or high cholesterol
In less than two years, the percentage of American adults using these meds for weight loss has roughly doubled, rising from 5.8% to 12%, according to a recent Gallup report
Tailored outreach methods may improve enrollment rates
Bellini MJ, Here CB, Goya RG, Garcia-Segura LM (2011) Insulin-like growth factor-I gene delivery to astrocytes reduces their inflammatory response to lipopolysaccharide